Results 191 to 200 of about 132,650 (237)

The influence of concomitant proton pump inhibitors use on treatment efficacy in hepatocellular carcinoma patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. [PDF]

Front Immunol
Duan Y, Zhao Q, Feng S, Jing W, Wang D, Zhang Y.   +5 more
europepmc   +1 more source

Proton pump inhibitors: perspectives of patients and their GPs.

, 2001
Andrew Williams
openalex  

Long term use of proton pump inhibitors and risk of stomach cancer: population based case-control study in five Nordic countries

BMJ
Duru O, Santoni G, Holmberg D, Birgisson H, Kauppila JH, von Euler-Chelpin M, Ness-Jensen E, Lagergren J.   +7 more
europepmc   +2 more sources

The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study. [PDF]

Medicina (Kaunas)
Hendem E, Koçak MZ, Çetinkaya AM, Dinç G, Çağlayan M, Uğraklı M, Çağlayan D, Araz M, Eryılmaz MK, Sakin A, Eren OÖ, Tatlı AM, Geredeli Ç, Artaç M.   +13 more
europepmc   +1 more source

In vitro susceptibility testing of Trichomonas gallinae strains to proton pump inhibitors and nitroimidazoles. [PDF]

Sci Rep
Kerek Á, Csiki BB, Szabó Á, Farkas M, Pitó A, Jerzsele Á, Mag P.   +6 more
europepmc   +1 more source

Concerns on Drug Interactions between Proton Pump Inhibitors and Clopidogrel: Unsafe Perspective

, 2011
Kyounghoon Lee, Seung Hwan Han
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Proton Pump Inhibitors

Annals of Pharmacotherapy, 2016
Objective: The purpose of this article is to describe the relationship between proton pump inhibitors (PPIs) and symptoms of myopathy based on case reports. Data Sources: A literature search was conducted in PubMed (1946 to June 2016) using MeSH terms proton pump inhibitors, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole ...
Evan W, Colmenares, Ashley L, Pappas
  +6 more sources

Deprescribing proton pump inhibitors

Australian Journal of General Practice, 2022
Proton pump inhibitors (PPIs) are indicated for disorders including peptic ulcer disease and gastro-oesophageal reflux disease; however, they are often used for longer and at higher doses than recommended, or for indications that are not supported by evidence.The aim of this article is to outline evidence-based approaches to deprescribing PPIs.PPIs are
Turner, Justin P., Thompson, Wade, Reeve, Emily, Bell, J. Simon   +3 more
openaire   +4 more sources

Proton pump inhibitors

Current Opinion in Gastroenterology, 2012
This review summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional deficiencies (B12 and magnesium), rebound acid hypersecretion, acute interstitial nephritis, gastric carcinoid tumor, cardiovascular risk with clopidogrel and PPI coprescription, bone fractures, enteric infections and pneumonia.
openaire   +3 more sources